Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02826460 · ClinicalTrials.gov registry record

Psychosocial Risks in Liver Transplant Recipients

A clinical trial of End Stage Liver DIsease, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
200
Enrollment target
1
Study location

NCT02826460 is a study of End Stage Liver DIsease that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 200 participants, below the 479-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02826460, a study of End Stage Liver DIsease, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

A retrospective chart review in which the information in the standard psychosocial evaluations done pre-transplant for liver transplant recipients will be coded, recorded, and correlated with posttransplant outcomes of the same recipients. Evaluated outcomes include rejection episodes and adherence to tacrolimus, calculated through the MLVI (Medication Level Variability Index). The researchers will evaluate the degree to which both single elements in the evaluation as well as a cumulative score derived by a structured review of the chart using the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) model can predict posttransplant outcomes.

Conditions Studied

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinia - New York

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2014-11
Est. Completion 2016-06

What the Registry Record Tells You About NCT02826460

The ClinicalTrials.gov registry entry for NCT02826460 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 479-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (58% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Liver DIsease appearing as the primary indexed condition, and to 0 interventions.

NCT02826460 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02826460 about?

NCT02826460 is a clinical study titled "Psychosocial Risks in Liver Transplant Recipients". A retrospective chart review in which the information in the standard psychosocial evaluations done pre-transplant for liver transplant recipients will be coded, recorded, and correlated with posttransplant outcomes of the same recipients. Evaluated outcomes include rejection episodes and adherence ...

What is the current status of trial NCT02826460?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2014-11. Estimated completion is 2016-06.

What conditions does trial NCT02826460 study?

This clinical trial studies the following conditions: End Stage Liver DIsease.

Who is sponsoring clinical trial NCT02826460?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02826460 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Liver DIsease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.